OSI | GenomeWeb


LAS VEGAS — Despite some recent setbacks, including ones in the RNAi field, oligonucleotide therapeutics are still likely to become the third major drug-development platform alongside small molecules and biologics in a matter of a few years, according to Art Krieg, the former CSO

Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.

In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.

OSI will have access to AVEO's tumor models, archives, and biomarkers and will also acquire non-exclusive access to AVEO's proprietary bioinformatics platform.

OSI officials this week said that the availability of a long-vacant biocampus, the presence of a nearby budding biocluster, the promise of tax breaks and other economic incentives — and discontent with leaders in its current home base in New York's Long Island region — persuaded it to bypass North Carolina and Pennsylvania in favor of the Westchester County site.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.